December 18, 2009, Newsletter Issue #50: How has Merck responded to charges of coverup in the case of Vioxx?
Tip of the Week
Merck Vice President Dennis Erb has defended the company's handling of Vioxx, noting that it promptly released details of studies that first raised the possibility of heart damage and followed up by performing the study that ultimately doomed the drug. "We believed wholeheartedly in the safety of Vioxx and that Vioxx was an important treatment option," he said. "My own father was a regular user of Vioxx until we voluntarily withdrew it from the market."
About LifeTips
Now one of the top on-line publishers in the world, LifeTips offers tips to millions of monthly visitors. Our mission mission is to make your life smarter, better, faster and wiser. Expert writers earn dough for what they know. And exclusive sponsors in each niche topic help us make-it-all happen.
